

# Index

## A

Actin polymerization, 6–8  
Activation-induced cytidine deaminase (AID) deficiency, 188  
Adaptive immunity, 170  
Alkaline phosphatase (ALP), 373  
AMD3100, 173  
Anaphylaxis, 281  
Anergy, 23  
Antibiotics  
  non-pharmacological interventions, 285  
  prophylaxis, 284  
  therapy, 285  
Antibody, 275  
Antibody affinity maturation, 27  
Antibody-secreting cells (ASC), 25, 125  
Antigen-presenting cells (APC)  
  antigen extraction, 10  
  antigen presentation to CD4<sup>+</sup>, 12–13  
  common variable immunodeficiency, 42  
  MHC molecules, antigen processing and loading on, 10–12  
  SSM, 4  
Anti-polysaccharide antibody deficiency, *see* Hypogammaglobulinemia  
APRIL protein, 29, 102, 103, 133–134  
Arterial thrombotic events, 281–282  
Arthritis, 268  
Aseptic meningitis, 281  
Ataxia telangiectasia mutated (ATM)  
  clinical presentation, 190  
  gene, 189–190  
  laboratory findings, 190  
  treatment and prognosis, 190–191  
Autoimmune-associated disorders, 266–267  
Autoimmune cytopenia, 45, 48, 107  
Autoimmune diseases, 229–230  
Autoimmune lymphoproliferative syndrome (ALPS), 116

Autoimmune phenomena, 160–161  
Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) syndrome, 159, 341  
Autoimmune polyglandular syndrome type 1 (APS1), 159  
Autoimmunity and inflammatory manifestations, 325–326  
  frequency, 326  
  management, 341–342  
  pathophysiological mechanisms, 326–341  
Autoimmunity, in CVID, 45  
Autophagy, 120

## B

*Bacillus* Calmette-Guérin vaccine (BCG), 293  
Bacterial infections, 160, 363–364  
B cell(s), 1  
  antigen-presenting cell, 4  
  APC  
    antigen extraction, 10  
    antigen presentation to CD4<sup>+</sup>, 12–13  
    MHC molecules, antigen processing and loading on, 10–12  
  contact with antigens, 3  
  direct antigen binding to BCR, 3–4  
  in vitro stimulation of, 92  
  lamellipodia, 8  
  response to antigen, 5–6  
  traffic, 2–3  
  transition of, 23  
B cell-activating factor receptor (BAFFR)  
  deficiency, 102, 103  
  CVID, 68–69  
  expression, 131–132  
  in humans, 139–141  
  ligand binding, 133–134

- B cell-activating factor receptor (BAFFR)  
 deficiency (*cont.*)  
 noncanonical NF- $\kappa$ B pathway activation,  
 134–136  
 PI3-kinase activation, 137  
 processing, 138  
 selection and autoimmunity, 139  
 target genes, 136
- B-cell lymphoma 6 (Bcl6), 13
- B-cell receptor (BCR)  
 clustering, 5–6  
 direct antigen binding, 3–4
- B-cell zones, 12
- BEACH domain-containing protein (BDGP),  
 122–124
- B lymphocytes, 131, 132  
 origin and development, 21–23
- Bronchiectasis, 349–351
- Bronchiolitis obliterans organizing pneumonia  
 (BOOP), 114
- Bronchus-associated lymphoid tissue  
 (BALT), 26
- Bruton tyrosine kinase gene (*BTK*), 347
- B-synapse, 8, 12–13
- C**
- cAMP response element binding protein  
 (CREB), 136
- Campylobacter jejuni*, 363
- Cancer, 45
- Candidiasis, 160
- Carbamazepine, 245
- C–C chemokine receptor type 5 (CXCR5), 79
- CD19 deficiency  
 antibody deficiency, 85–88  
 B cells, 92  
 clinical and immunological characteristics,  
 88–91  
 complement-independent recruitment, 92  
 complex function and gene expression  
 levels, 84  
 CVID, 69  
 diagnosis and prognosis, 92–93  
 genetic defects, 88  
 identification and characterization, 83–85  
 impaired antibody responses, 91–92
- CD20, 83
- CD21, 83, 91
- CD81 and CD225, 83–85
- CD21 deficiency  
 clinical manifestations, 98  
 definition, 97  
 diagnosis, 98
- etiology, 97–98  
 immunological phenotype, 98
- CD40L and CD40 deficiency  
 clinical presentation, 184  
 genes, 183–184  
 laboratory results, 184  
 treatment and prognosis, 184–186 (*see also*  
 Class-switch recombination (CSR)  
 defects)
- CD8<sup>+</sup> T cells, 12–13
- Celiac disease, 44, 371–372
- Central supramolecular activation cluster  
 (cSMAC), 5
- Central tolerance, 23
- Centroblasts, 13
- Centrocytes, 13
- Chediak-Higashi syndrome (CHS), 123
- Chemokine CXCL12, 168
- Chest infections  
 airway infections, 348  
 bronchiectasis, 349–351  
 interstitial lung diseases, 351–355  
 MALTOMA, 355  
 respiratory infections, 349  
 upper and lower tract infections, 348
- Chest X-ray (CXR), 350
- Chromosomal abnormalities  
 18q syndrome, 238  
 trisomy 8, 238–239  
 trisomy 21, 239
- Chronic hepatitis, 373
- Citrobacter rodentium*, 108
- Class II-associated invariant chain peptide  
 (CLIP), 11
- Class-switch recombination (CSR) defects,  
 27–28  
 biological mechanism, 179  
 DNA repair defects  
 ataxia telangiectasia, 189–191  
 DNA ligase 4 and cernunnos, 193–194  
 Nijmegen breakage syndrome, 191–193  
*PMS2*, *MHL1*, *MSH2*, and *MHS6* and  
 deficiency, 194–195  
 estimated frequency, 182  
 germinal center reaction, 179–181  
 intrinsic B-cell defects  
 AID deficiency, 188  
 UNG deficiency, 188–189  
 molecular level, 182, 183  
 somatic hypermutation, 181–182  
 T-B interaction  
 CD40L and CD40 deficiency, 183–186  
 NEMO deficiency, 186–187
- Colitis, 372

- Common variable immunodeficiency (CVID),  
 57–59, 297–298  
 antigen-presenting cells, 42  
 autoimmunity, 45  
 B-cell abnormalities, 40–42  
 cancer, 45  
 clinical manifestations, 67  
   infections, 43–44  
   noninfectious manifestations, 44–45  
 cohorts, 59–61  
 definition, 35, 316  
 DEFI study, 59, 60  
 diagnosis criteria, 61–62  
 diagnostic criteria, 35–37, 46–47  
 etiology, 36–38  
 gastric adenocarcinoma, 319  
 gastrointestinal disease, 44  
 genetics  
   BAFFR, 68–69  
   CD19 deficiency, 69  
   CTLA-4, 71  
   DNA repair process, 72  
   genetic cause, 67  
   heterozygous variants, 68  
   ICOS deficiency, 67–68  
   LRBA deficiency, 70–71  
   NF- $\kappa$ B pathway, 71  
   PI3K pathway, 70  
   PRKCD deficiency, 70  
   RAG1/2 mutations, 72  
   TACI mutations, 68  
   *TNFRSF13C*, 68–69  
   TWEAK deficiency, 70  
 immunopathology, 38  
 innate immunity, 43  
 lung disease, 44  
 lymphoma, 318–319  
 lymphoproliferation, 45  
 management, 48–49  
 next-generation sequencing, 62–63  
 T-cell abnormalities, 38–39  
 T cell function, 58  
 Computed tomography (CT), 350  
 Conduits, 2, 3  
 Conjugate polysaccharide vaccines, 301  
 Constitutional mismatch repair deficiency  
   syndromes (CMMRD), 194–195  
 C104R/C104Y, 106, 139  
 CR2 knockout mice, 97–98  
*Cryptosporidium*, 184, 363  
 CSR defects, *see* Class-switch recombination  
   (CSR) defects  
 CVID, *see* Common variable  
   immunodeficiency (CVID)
- CXCL13, 9  
 CXCR4, 167–169  
 Cyclophosphamide, 244  
 Cysteine-rich domains (CRDs), 131  
 Cytomegalovirus (CMV), 243, 365  
 Cytopenias, 282  
 Cytotoxic T lymphocyte antigen 4 (CTLA-4),  
 71, 77, 116, 119
- D**
- Dendritic cells (DC), 42  
 Disease-modifying drugs  
   (DMARDs), 342  
 DNA ligase 4 and cernunnos, 193–194  
 DNA repair defects  
   ataxia telangiectasia  
     clinical presentation, 190  
     gene, 189–190  
     laboratory findings, 190  
     treatment and prognosis, 190–191  
   DNA ligase 4 and cernunnos, 193–194  
   Nijmegen breakage syndrome  
     clinical presentation, 192  
     gene, 191–192  
     laboratory findings, 192  
     treatment and prognosis, 192–193  
   *PMS2*, *MHL1*, *MSH2*, and *MHS6* and  
     deficiency, 194–195 (*see also*  
     Class-switch recombination (CSR)  
     defects)
- Down syndrome, 239  
 Dynein motor complexes, 9  
 Dyspnea, 282
- E**
- Electrolyte imbalances, 283  
 Enteropathy, 267  
 Epstein-Barr virus (EBV) infections, 243  
 Esophagus, 367  
 EUROclass classification, 41  
 European Society for Immune Deficiencies  
   (ESID), 35, 57  
 Ezrin-radixin-moesin (ERM), 6
- F**
- Fenclofenac, 244  
 Fibroblastic reticular cells (FRC), 2  
*Flexispira rappini*, 285  
 Follicular (FO) B cells, 23  
 Follicular dendritic cells (FDC), 3  
 “Freiburg” classification, 40

**G**

- Gastric adenocarcinoma, 319
- Gastrointestinal (GI) complications
- bacterial infections, 363–364
  - colon, 372
  - concrete diseases, 366–367
  - esophagus, 367
  - inflammatory complications, 365
  - liver, 373
  - malignancy, 365–366
  - mouth cavity, 367
  - prevalence, 361–363
  - protozoal infections, 364
  - small intestine
    - IgAD and celiac disease, 371–372
    - nodular lymphoid hyperplasia, 369
    - villous flattening, 369–371
  - stomach, 368–369
  - viral infections, 364–365
- Gastrointestinal disease, 44
- Gastrointestinal infections, 285
- Gastrointestinal tract (GIT), 361
- Germinal centers (GCs), 13
- Giardia lamblia*, 184, 364
- Glucocorticosteroids, 244
- Gold salts, 245
- Good's syndrome (GS)
- clinical presentation
    - autoimmune diseases, 229–230
    - infections, 228–229
  - diagnosis and differential diagnosis, 231
  - hematology, 230
  - immunological hallmark, 230–231
  - incidence, etiology and pathogenesis, 227–228
  - laboratory features, 230–231
  - prognosis, 232
  - treatment, 231–232
- G protein-coupled receptors (GPCRs), 2
- Graft-versus-host disease (GvHD), 125
- Granulomatous and lymphocytic interstitial lung disease (GLILD), 352
- GS, *see* Good's syndrome (GS)
- Gut-associated lymphoid tissue (GALT), 24–25

**H**

- Haemophilus influenzae*, 28
- Haemophilus influenzae* type B (Hib), 293, 299–300
- Headache, 281
- Health-related quality of life (HRQL), 208
- Helicobacter bilis*, 285

- Helicobacter pylori* (*H. pylori*), 28–29, 43, 363
- Hematopoietic stem cell transplantation (HSCT), 48–49, 122, 286
- with rituximab, 242
  - vaccinations, 305
- Hemolysis, 282
- Heparan sulfate proteoglycans (HSPG), 134
- Hepatitis C (HCV), 283
- Herd immunity, 308
- HLA-DM, 11
- Hyaluronidase-facilitated subcutaneous immunoglobulins, 261
- Hypogammaglobulinemia, 98, 115, 168
- age of onset, 236
  - with antibody deficiency, 235
  - after B-cell targeting therapy, 245–247
  - after bone marrow transplantation, 242
  - cause, 235
  - chromosomal abnormalities
    - 18q syndrome, 238
    - trisomy 8, 238–239
    - trisomy 21, 239
  - in chronic lymphocytic leukemia, 241–242
  - clinical features, 220–221
  - congenital AIDS, 242–243
  - definitions, 217
  - diagnosis and laboratory features, 221–222
  - differential diagnosis, 237
  - drug-induced
    - carbamazepine, 245
    - cyclophosphamide and mycophenolate, 244
    - fenclofenac, 244
    - glucocorticosteroids, 244
    - gold salts, 245
    - penicillamine, 245
    - phenytoin, 245
    - sulfasalazine, 245
    - valproic acid, 245
  - epidemiology, 218–219
  - after immunosuppressive regimens, 248
  - management and treatment, 222–224
  - in multiple myeloma, 242
  - pathophysiology, 219–220
  - primary, 236–238
  - protein-losing syndromes, 243
  - secondary immune deficiencies
    - classical conditions, 239, 241
    - malignancies, 241–242
  - secondary to short immunoglobulin half-life, 243–244
  - subgroups, 218
  - viral infections, 242–243

**I**

- ICOS deficiency, *see* Inducible costimulator (ICOS) deficiency
- IgA deficiency (IgAD), 254–255, 371–372  
 clinical features, 206  
 cytokine stimulation, 205  
 definition, 201–202  
 diagnosis and laboratory features, 207  
 epidemiology, 202  
 frequency, 202  
 genetic basis, 203–204  
 management and treatment, 207–208  
 pathogenesis, 203  
 IgA production, 26–28, 205
- ILD, *see* Interstitial lung diseases (ILD)
- Immature B cells, 22–23
- Immune dysregulation, 114
- Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX), 116
- Immune synapse, 1  
 antigen recognition, 5  
 BCR clustering, 5–6  
 definition, 5  
 two-phase assembly  
   control B cell spreading, 6–8  
   microtubules and microfilaments, 8–9
- Immunoglobulin replacement therapy, 48  
 adverse reactions and side effects, 280–281  
 from donor to recipient, 276  
 facilitated subcutaneous  
   immunoglobulins, 278  
 goal, 27–280  
 history, 275  
 intravenous immunoglobulins, 276–277, 279  
 starting, 278–279  
 subcutaneous immunoglobulins, 277–279  
 trough level, 279–280
- Immunoglobulins G (IgG) subclass deficiency, 219–220, 255–256
- Immunoglobulin therapy, 207, 256–257, 301–302
- Immunosuppressive drugs, 302
- Immunosuppressive therapy, 122
- Inactivated influenza vaccine (IIV), 296
- Inducible costimulator (ICOS) deficiency  
 clinical manifestations, 79–80  
 CVID, 67–68  
 definition, 77  
 diagnosis, 80  
 etiology, 77–79  
 management, 80  
 signaling pathways, 78  
 vaccination, 298
- Infectious disease, 159–160

- Innate immunity, 169
- Innate lymphoid cells (ILC), 14, 43
- Integrin activation, 8
- International Union of Immunological Societies (IUIS) Expert Committee for Primary Immunodeficiency, 59, 292, 315
- Interstitial lung diseases (ILD)  
 acid-fast bacilli, 353  
 CT, 351  
 excessive lymphadenopathy, 352  
 GLILD, 352  
 Gomori methenamine-silver stains, 353  
 histological features, 352–353  
 immunosuppressive agents, 355  
 predictive markers, 354  
 splenomegaly, 354
- Intravenous immunoglobulin (IVIG), 174, 257, 276–277, 279  
 immediate infusion reactions, 280–281
- Intrinsic B-cell defects  
 AID deficiency, 188  
 UNG deficiency, 188–189
- J**
- Janus kinase 3 (*JAK3*), 62
- L**
- Lamellipodia, extension of, 8
- Laryngeal associate lymphoid tissue (LALT), 26
- Late-onset combined immunodeficiency (LOCID), 39  
 definition, 59–61  
 next-generation sequencing, 62–63
- Lipopolysaccharideresponsive beige-like anchor (LRBA) deficiency  
 biological characteristics, 122–124  
 clinical manifestations, 113  
 clinical onset, 116  
 hypogammaglobulinemia, 115  
 immune dysregulation, 114  
 neurologic complications, 115–116  
 organomegaly, 114  
 recurrent infections, 114–115
- CVID, 70–71  
 diagnosis, 121  
 differential diagnosis, 117–118  
 etiology, 114  
 laboratory findings, 120–121  
 management and treatment, 122  
 mouse model, 124–126  
 pathophysiology, 119–120  
 vaccination, 298

- Liver diseases, 373
- LOCID, *see* Late-onset combined immunodeficiency (LOCID)
- LRBA deficiency, *see*  
Lipopolysaccharideresponsive beige-like anchor (LRBA) deficiency
- Lung disease  
in COVID, 44  
manifestations, 161
- Lymphocytic choriomeningitis virus (LCMV), 125
- Lymphoma, 318–319
- Lymphoproliferative disorders, 45, 114
- M**
- Major antibody defects management  
arthritis, 268  
autoimmune complications, 266–267  
comorbidities and complications, 262  
GI complications and enteropathy, 267  
hyaluronidase-facilitated subcutaneous immunoglobulins, 261  
immunoglobulin therapy, 256–257  
infectious complications, 262–264  
intravenous immunoglobulin, 257  
malignancy, 267–268  
polyclonal lymphocyte infiltrative complications, 265–266  
pulmonary complications, 264–265  
subcutaneous rapid push, 261  
subcutaneous therapy, 257–261
- Major histocompatibility complex (MHC), 10–12, 204
- MALT, *see* Mucosa-associated lymphoid tissue (MALT)
- MALToma, 28–29, 355
- Marginal zone (MZ) B cells, 22–23
- MB1 and 2, 40
- Measles/mumps/rubella (MMR), 295–297, 300, 302
- MHC-II compartments (MIICs), 11
- MHC-I molecules, 11–12
- MHC-II molecules, 10–11
- Microfilaments, 8–9
- Microsignalosomes, 6
- Microtubule(s), 8–9
- Microtubule-organizing center (MTOC), 8–9
- Mild antibody deficiencies, 292, 293, 294
- Milder hypogammaglobulinemia, 219
- Minor antibody defects management  
IgG subclass deficiency, 255–256  
selective IgA deficiency, 254–255
- Moraxella catarrhalis*, 28
- Mouth cavity, 367
- Mucosa-associated lymphoid tissue (MALT)  
BALT, 26  
characteristics, 24  
follicle-associated epithelium, 25  
GALT, 24–25  
gastrointestinal tract, 25  
IgA<sup>+</sup>CD27<sup>+</sup> cells, 25  
LALT, 26  
lymphoma, 28–29  
NALT, 26  
subregions, 23
- Mucosal B cells, 23–26
- Multicomponent assembly, 6
- Multiphoton microscopy techniques, 3
- Mycophenolate, 244
- MyD88, 173
- Myeloid dendritic cells (mDCs), 42
- N**
- Nasal-associated lymphoid tissue (NALT), 26
- NBS, *see* Nijmegen breakage syndrome (NBS)
- NEMO deficiency, 186–187
- Neurogenic locus notch homolog protein 2 (NOTCH2), 22
- Next-generation sequencing (NGS), 62–63
- NFKB2* defects  
clinical manifestations, 158–159  
autoimmune phenomena, 160–161  
infectious disease, 159–160  
lung disease manifestations, 161
- diagnosis, 162  
genetic and molecular basis, 157–158  
laboratory features, 161–162  
management, 162–163  
signaling pathway, 153–154  
canonical, 154  
noncanonical, 154–157
- NF-κB proteins, 134
- Nijmegen breakage syndrome (NBS)  
clinical presentation, 192  
gene, 191–192  
laboratory findings, 192  
treatment and prognosis, 192–193 (*see also* Class-switch recombination (CSR) defects)
- NIK protein, 136
- Nodular lymphoid hyperplasia (NLH), 44, 369
- Nodular regenerative hyperplasia (NRH), 44, 373
- Noncanonical NF-κB pathway  
activation, 134–136  
murine model, 155–157

Nonviable vaccines, 292, 296, 298

*Norovirus*, 285

## O

Organomegaly, 114

## P

Pan-American Group for Immunodeficiency (PAGID), 35, 57

Parasitic infections, 160

“Paris” classification, 40

Parvovirus B19, 283

Penicillamine, 245

Peripheral SMAC (pSMAC), 5

Phenytoin, 245

Phosphatidylinositol-3-kinase (PI3K), 78

PI3-kinase activation, 137

Plasma cells, 25

Plasmacytoid dendritic cells (pDCs), 42

*PMS2*, *MHL1*, *MSH2*, and *MHS6* and deficiency, 194–195

*Pneumocystis jirovecii* pneumonia (PJP), 162, 184

Polyclonal lymphocyte infiltrative complications, 265–266

PPV13/PPSV23, 300

Predominantly antibody deficiency (PAD)

IUIS classification, 316–317

predisposition to malignancies, 316–318  
vaccinations, 291–292

combined immunodeficiency, 298

diagnostic use, 305–308

ICOS and LRBA deficiency, 298

mild antibody deficiencies, 293, 294

principles, 292

PRKC delta deficiency, 298

severe antibody deficiencies, 296–297

specific mild antibody deficiencies,  
293, 295–296

specific severe antibody deficiencies,  
297–298

susceptibility, 299–300

TWEAK defects, 298

WHIM syndrome, 299 (*see also*

Common variable  
immunodeficiency (CVID))

Primary antibody deficiency (PAD), 27

autoimmunity and chronic inflammation,  
326–341

chest infections

airway infections, 348

bronchiectasis, 349–351

interstitial lung diseases, 351–355

MALTOMA, 355

respiratory infections, 349

upper and lower tract infections, 348

gastrointestinal complications

bacterial infections, 363–364

colon, 372

concrete diseases, 366–367

esophagus, 367

inflammatory complications, 365

liver, 373

malignancy, 365–366

mouth cavity, 367

prevalence, 361–363

protozoal infections, 364

small intestine, 369–372

stomach, 368–369

viral infections, 364–365

management of patients with, 341–342

Primary hypogammaglobulinemia,  
236–238

Primary immunodeficiency (PID)

autoimmunity and inflammatory  
manifestations, 325–326

frequency, 326

management, 341–342

pathophysiological mechanisms,  
326–341

inflammatory complications, 253

major antibody defects management

arthritis, 268

autoimmune complications, 266–267

comorbidities and complications, 262

GI complications and enteropathy, 267

hyaluronidase-facilitated subcutaneous  
immunoglobulins, 261

immunoglobulin therapy, 256–257

infectious complications, 262–264

intravenous immunoglobulin, 257

malignancy, 267–268

polyclonal lymphocyte infiltrative  
complications, 265–266

pulmonary complications, 264–265

subcutaneous rapid push, 261

subcutaneous therapy, 257–261

minor antibody defects management

IgG subclass deficiency, 255–256

selective IgA deficiency, 254–255

(*see also specific types*)

Primary lymphoid follicles, 12

PRKCD deficiency

CVID, 70

vaccination, 298

Prophylactic antibiotics, 284, 349

Protein-losing syndromes, 243  
 Protozoal infections, 364  
*Pseudomonas aeruginosa*, 284  
 Pulmonary complications, 264–265, 282  
 Pulmonary function tests, 264

## Q

18q syndrome, 238

## R

Recombination-activating genes (*RAG*), 62  
 Rel homology domain (RHD), 153  
 Renal failure, 283  
 Respiratory infections, 159–160  
 Rhinoviral infections, 349  
 Rituximab, 342

## S

Secondary hypogammaglobulinemia  
   classical conditions, 239, 241  
   malignancies, 241–242 (*see also*  
     Hypogammaglobulinemia)  
 Selective IgA deficiency (SIgAD), 255, 293,  
 295–296, 347  
 Severe antibody deficiencies, 296–297  
*sIgGdef*, 218  
*sIgGscdef*, 218  
*sIgMdef*, 218  
 Signalosome, 6  
 Signal transducer and activator of  
   transcription 3 (STAT3), 116  
 Small intestine  
   IgAD and celiac disease, 371–372  
   nodular lymphoid hyperplasia, 369  
   villous flattening, 369–371  
 Smith-Magenis syndrome (SMS), 106  
 Somatic hypermutation (SHM), 27–28, 42,  
 181–182  
 Steroids, 341–342  
 Stomach, 368–369  
*Streptococcus pneumoniae*, 104  
 Subcapsular sinus (SSM), 4  
 Subcutaneous administration of IgG (SCIG),  
 256, 259–261, 277–279  
 Subcutaneous immunoglobulin  
   therapy, 261  
 Sulfasalazine, 245  
 Synthetic CTLA-4-Ig, 342

## T

TACI deficiency  
   definition, 101  
   diagnosis and management, 108  
   etiology, 101–105  
   immunological and clinical  
     manifestations, 105–108  
 TACI mutations, 68  
 TBK1, 79  
 Tetralogy of Fallot (TOF), 172–173  
 T-helper cells (TFH), 79  
 Thrombotic complications, 281–282  
 T-independent IgA production, 28  
 TNF-like weak inducer of apoptosis  
   (TWEAK) deficiency  
   clinical manifestations, 150–151  
   COVID, 70  
   definition, 149  
   diagnosis, 151  
   etiology, 149–150  
   vaccination, 298  
*TNFRSF13C*, 68–69  
 Tonsils, 26  
 Total internal reflection microscopy  
   (TIRFM), 6  
 Transfusion-related acute lung injury  
   (TRALI), 282  
 Trisomy 8, 238–239  
 Trisomy 21, 239  
 T-synapse, 12–13  
 TWEAK-Fn14 pathway, 150

## U

Unclassified primary antibody deficiency  
   (unPAD), 218  
 Uracil-DNA glycosylase (UNG) deficiency,  
 188–189

## V

Vaccinations  
   herd immunity, 308  
   household contacts of patients, 303  
   HSCT, 305  
   immunoglobulin therapy, 301–302  
   immunosuppressive drugs, 302  
   in predominantly antibody deficiency,  
     291–292  
   combined immunodeficiency, 298  
   diagnostic use, 305–308



- ICOS and LRBA deficiency, 298
  - mild antibody deficiencies, 293, 294
  - principles, 292
  - PRKC delta deficiency, 298
  - severe antibody deficiencies,
    - 296–297
  - specific mild antibody deficiencies,
    - 293, 295–296
  - specific severe antibody deficiencies,
    - 297–298
  - susceptibility, 299–300
  - TWEAK defects, 298
  - WHIM syndrome, 299
    - in pregnancy, 303
    - for travel in patients, 304–305
  - Valproic acid, 245
  - Varicella (VAR) vaccines, 295–297, 300,
    - 302, 303
  - Venous thrombosis, 282
  - Viable vaccines, 292
  - Viral infections, 160, 364–365
- W**
- Waldenstrom macroglobulinemia (WM), 173
  - Warts, hypogammaglobulinemia, infections,
    - myelokathexis (WHIM) syndrome
      - in adaptive immunity, 170
      - of B cell activation, 171–172
    - CXCR4, 167–169
    - definition, 167–168
    - hypogammaglobulinemia, 168
    - in innate immunity, 169
    - of T cell activation, 170–171
    - tetralogy of Fallot, 172–173
    - therapeutic regimens, 173–174
    - vaccination, 299
    - Waldenstrom macroglobulinemia, 173
  - Wheezing, 282
- X**
- X-linked agammaglobulinemia (XLA),
    - 320, 347